Literature DB >> 18034424

The activity of lipopeptide TLR2 agonists critically depends on the presence of solubilizers.

Söhnke Voss1, Artur J Ulmer, Günther Jung, Karl-Heinz Wiesmüller, Roland Brock.   

Abstract

Lipoproteins activate cells of the innate immune system via heteromers of Toll-like receptor (TLR) 2 with either TLR1 or TLR6. In spite of progress in understanding TLR-dependent signal transduction and the pathophysiological relevance of TLR2, the molecular basis of ligand recognition by this receptor is poorly defined. Here, we show that the bioactivity of lipopeptides (LP) critically depends on the dilution protocol and especially the presence of proteins or detergents acting as solubilizers. Fluorescence correlation spectroscopy of fluorescently labeled analogs of synthetic LP revealed that the LP form aggregates in solution. Dilution into protein- and serum-free buffers led to a complete loss of activity due to formation of large and highly heterogeneous aggregates. When dimethylsulfoxide stock solutions were diluted into BSA or serum-containing buffers particles of strongly reduced size were obtained. For some LP, an intermediary dilution step either with tert.-butyl alcohol/H2O (4:1) or with octyl-beta-D-glucopyranoside further increased activity. For a panel of LP exhibiting very different activities when diluted directly into protein-containing solutions, introduction of this dilution step resulted in comparable bioactivities. These results demonstrate the significance of solubilizing agents for the bioactivity of LP and are highly relevant for analyzing structure-activity relationships of LP-dependent TLR2 activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18034424     DOI: 10.1002/eji.200737537

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

Review 1.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

2.  Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.

Authors:  Takashi Akazawa; Toshimitsu Ohashi; Viskam Wijewardana; Kikuya Sugiura; Norimitsu Inoue
Journal:  Cancer Sci       Date:  2018-04-22       Impact factor: 6.716

3.  Natural killer T cells activated by a lipopeptidophosphoglycan from Entamoeba histolytica are critically important to control amebic liver abscess.

Authors:  Hannelore Lotter; Nestor González-Roldán; Buko Lindner; Florian Winau; Armando Isibasi; Martha Moreno-Lafont; Artur J Ulmer; Otto Holst; Egbert Tannich; Thomas Jacobs
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

4.  Toll-like receptor 2 regulates the barrier function of human bronchial epithelial monolayers through atypical protein kinase C zeta, and an increase in expression of claudin-1.

Authors:  Sakthikumar Ragupathy; Farnaz Esmaeili; Serge Paschoud; Emmanuelle Sublet; Sandra Citi; Gerrit Borchard
Journal:  Tissue Barriers       Date:  2014-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.